JP4607484B2 - ガン転移抑制剤 - Google Patents
ガン転移抑制剤 Download PDFInfo
- Publication number
- JP4607484B2 JP4607484B2 JP2004115615A JP2004115615A JP4607484B2 JP 4607484 B2 JP4607484 B2 JP 4607484B2 JP 2004115615 A JP2004115615 A JP 2004115615A JP 2004115615 A JP2004115615 A JP 2004115615A JP 4607484 B2 JP4607484 B2 JP 4607484B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- cancer metastasis
- solvent
- minutes
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 52
- 201000011510 cancer Diseases 0.000 title claims description 50
- 239000002257 antimetastatic agent Substances 0.000 title claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 32
- 241000222336 Ganoderma Species 0.000 claims description 31
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 238000000862 absorption spectrum Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 description 39
- 230000009401 metastasis Effects 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 239000000284 extract Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003463 adsorbent Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- -1 poultice Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000906988 Ganoderma atrum Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
1.
下記に示される、(1)〜(5)のすべての条件を満たす成分を含有することを特徴とする、ガン転移抑制剤。
(1)黒霊芝のエタノール抽出物に含有する成分である。
(2)赤外吸収スペクトルを測定すると(KBr法)、2925、1700、1600、1455、1170、835cm −1 に吸収の極大を示す。
(3)本成分をエタノールに溶解し、紫外吸収スペクトルを測定すると、280〜330nmに吸収の極大を示す。
(4)分子内に芳香環を含有する。
(5)本成分に酢酸エチルを加えたとき、酢酸エチル可溶分の溶液は着色性であり、茶色〜赤褐色を示す。
2.
下記(A)〜(F)の条件にてHPLC分析を行い、図1に示される、保持時間が10〜25分のブロードなピークを有する成分を含有することを特徴とする、上記1.に記載のガン転移抑制剤。
分析条件
(A)HPLCカラム:ODS(オクタデシル化シリカゲル)
(B)HPLCカラム温度:40℃
(C)展開溶媒
0.2%リン酸/0.2%リン酸を含有するアセトニトリルを用い、0.2%リン酸を含有するアセトニトリルを20%から100%に20分かけて直線的に溶媒を変化させ、100%で25分保持する(45分分析)。
(D)流速:1mL/分
(E)検出:313nm
(F)試料:10mg/mLのエタノール溶液を20マイクロL導入
(A)カラム:オクタデシル化シリカゲル(ODS、内径4.5mm×250mm)
(B)カラム温度:40℃
(C)展開溶媒:0.2%リン酸/0.2%リン酸を含有するアセトニトリルを用い、0.2%リン酸を含有するアセトニトリルを20%から100%に20分かけて直線的に溶媒を変化させ、100%で25分保持する(計45分分析)。
(D)流速:1mL/分
(E)検出:313nm
(F)試料:10mg/mLのエタノール溶液を20マイクロL導入
黒霊芝子実体の乾燥物1Kgにエタノール15Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、黒霊芝のエタノール抽出物を20g得た。このうち、黒霊芝のエタノール抽出物0.50gを分取HPLCにより精製し、黒霊芝のガン転移抑制成分を0.21g得た。なお、HPLCの分画範囲は、0013段落に記載の範囲とした。
<HPLC分画条件>
(A)充填剤:ODS(内径20mm×長さ250mm)
(B)展開溶媒
0.2%リン酸/0.2%リン酸を含有するアセトニトリルを用い、0.2%リン酸を含有するアセトニトリルを20%から100%に20分かけて直線的に溶媒を変化させ、100%で25分保持する。
(C)流速:10mL/分
(D)検出:350nm
赤外吸収スペクトル分析
製造例1の黒霊芝の溶媒分画物をKBr法で赤外吸収スペクトルを測定した。その結果、約3294、2926、1698、1604、1456、1169、823cm−1に吸収の極大を示した。
紫外吸収スペクトル分析
製造例1の黒霊芝の溶媒分画物5mgを100mLのエタノールに溶解し、紫外吸収スペクトルを測定した。その結果、295、313nmに吸収の極大を示した。
NMRスペクトル分析
製造例1の黒霊芝の溶媒分画物を用い、定法により1H、13C−NMR分析した結果、6.6〜7.6ppm(1H−NMR)、100〜150ppm(13C−NMR)にスペクトル吸収を認め、芳香環の存在が確認された。なお、溶媒は重メタノール(CD3OD)を用いた。
製造例1で製造した抽出物を用いた。
処方 配合量
1.黒霊芝のガン転移抑制成分(製造例1) 20部
2.乾燥コーンスターチ 30
3.微結晶セルロース 50
[製法]成分1〜3を混合し、散剤とする。
処方 配合量
1.黒霊芝のガン転移抑制成分(製造例1) 0.5部
2.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
3.モノステアリン酸グリセリン 10.0
4.流動パラフィン 5.0
5.セタノール 6.0
6.パラオキシ安息香酸メチル 0.1
7.プロピレングリコール 10.0
8.精製水 66.4
[製造方法]成分2〜5を加熱溶解して混合し、70℃に保ち油相とする。成分1および6〜8を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
C57BL/6マウスに対し、黒霊芝のガン転移抑制成分(製造例1)を1日1回、100mg/kgとなるように腹腔経路にて1週間連続投与を行った。対照群には生理食塩水を腹腔内投与した。動物の例数は一群8匹とした。次いで、B16マウスメラノーマ細胞をマウス1匹あたり1×105個となるように尾静脈より注入した。その後も試料の投与は継続し、ガン細胞の接種から3週間後に肺を摘出し、10%ホルマリン溶液中で固定した。ホルマリン固定した肺を5葉に分割し、表面に形成された転移巣の数をカウントした。その結果、表1に示すように、黒霊芝のガン転移抑制成分の投与により転移巣の形成は対照群と比較して有意に抑制され、極めて高い転移抑制効果を有することがわかった。
Claims (2)
- 下記に示される、(1)〜(5)のすべての条件を満たす成分を含有することを特徴とする、ガン転移抑制剤。
(1)黒霊芝のエタノール抽出物に含有する成分である。
(2)赤外吸収スペクトルを測定すると(KBr法)、2925、1700、1600、1455、1170、835cm −1 に吸収の極大を示す。
(3)本成分をエタノールに溶解し、紫外吸収スペクトルを測定すると、280〜330nmに吸収の極大を示す。
(4)分子内に芳香環を含有する。
(5)本成分に酢酸エチルを加えたとき、酢酸エチル可溶分の溶液は着色性であり、茶色〜赤褐色を示す。 - 下記(A)〜(F)の条件にてHPLC分析を行い、図1に示される、保持時間が10〜25分のブロードなピークを有する成分を含有することを特徴とする、請求項1に記載のガン転移抑制剤。
分析条件
(A)HPLCカラム:ODS(オクタデシル化シリカゲル)
(B)HPLCカラム温度:40℃
(C)展開溶媒
0.2%リン酸/0.2%リン酸を含有するアセトニトリルを用い、0.2%リン酸を含有するアセトニトリルを20%から100%に20分かけて直線的に溶媒を変化させ、100%で25分保持する(45分分析)。
(D)流速:1mL/分
(E)検出:313nm
(F)試料:10mg/mLのエタノール溶液を20マイクロL導入
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004115615A JP4607484B2 (ja) | 2004-04-09 | 2004-04-09 | ガン転移抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004115615A JP4607484B2 (ja) | 2004-04-09 | 2004-04-09 | ガン転移抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005298391A JP2005298391A (ja) | 2005-10-27 |
JP4607484B2 true JP4607484B2 (ja) | 2011-01-05 |
Family
ID=35330372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004115615A Expired - Lifetime JP4607484B2 (ja) | 2004-04-09 | 2004-04-09 | ガン転移抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4607484B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5085120B2 (ja) * | 2006-12-21 | 2012-11-28 | 日本メナード化粧品株式会社 | 脳機能改善剤 |
CN103880970A (zh) * | 2012-12-20 | 2014-06-25 | 上海医药工业研究院 | 采用离子交换树脂对紫芝液体深层发酵菌丝体粗多糖进行脱色的方法 |
JP6469476B2 (ja) * | 2015-02-26 | 2019-02-13 | 日本メナード化粧品株式会社 | 外用剤及び内用剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57112331A (en) * | 1980-12-29 | 1982-07-13 | Toyo Yakushiyoku Kogyo Kk | Medical composition of ganoderma lucidum component |
JP2003104904A (ja) * | 2001-09-28 | 2003-04-09 | Nonogawa Shoji Kk | 高血圧抑制剤 |
JP2003171307A (ja) * | 2001-09-27 | 2003-06-20 | Nonogawa Shoji Kk | マトリックスメタロプロテアーゼ阻害剤 |
-
2004
- 2004-04-09 JP JP2004115615A patent/JP4607484B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57112331A (en) * | 1980-12-29 | 1982-07-13 | Toyo Yakushiyoku Kogyo Kk | Medical composition of ganoderma lucidum component |
JP2003171307A (ja) * | 2001-09-27 | 2003-06-20 | Nonogawa Shoji Kk | マトリックスメタロプロテアーゼ阻害剤 |
JP2003104904A (ja) * | 2001-09-28 | 2003-04-09 | Nonogawa Shoji Kk | 高血圧抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2005298391A (ja) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
TWI648257B (zh) | 牛樟芝化合物、製備方法及其用途 | |
WO2000039249A1 (fr) | Extrait de prune umeboshi a effets medicamenteux et compositions associees | |
JP5085120B2 (ja) | 脳機能改善剤 | |
JP2711630B2 (ja) | 皮膚外用剤 | |
WO2022215441A1 (ja) | 新規ポリフェノール化合物 | |
CN101472597B (zh) | 核转录因子ap-1的表达抑制剂及使用其的药品和制品 | |
CN105777685A (zh) | 一种非洛地平的药物组合物及其医药用途 | |
JP4607484B2 (ja) | ガン転移抑制剤 | |
JP3742084B2 (ja) | 特定の抽出法によるマンネンタケ抽出物とその製造方法 | |
JP6923100B1 (ja) | 新規イソフラボン化合物 | |
KR20070024147A (ko) | 리포좀으로 안정화 된 우렁쉥이 또는 멍게 외막 추출물을함유하는 피부 노화 억제 및 주름 개선 화장료 조성물 | |
JP6143167B2 (ja) | 小眼球症関連転写因子抑制剤、メラニン産生抑制剤、化粧品組成物及び抗ガン剤 | |
JP6919960B1 (ja) | 新規フェニルプロパノイド化合物 | |
JPH05345705A (ja) | 美白化粧料組成物 | |
JP2003277271A (ja) | 抗癌剤 | |
KR100836941B1 (ko) | 차가버섯으로부터 분리된 항산화 화합물 및 이를 포함하는 조성물 | |
JP4536360B2 (ja) | 抗血栓剤 | |
JPH07330624A (ja) | 抗炎症、抗かゆみ剤 | |
JP5649995B2 (ja) | セラミド産生促進剤 | |
JPH05345719A (ja) | 美白化粧料組成物 | |
JP2003113088A (ja) | 発ガンプロモーター抑制剤及びそれを含有する組成物 | |
JP6969041B2 (ja) | 血管内皮型一酸化窒素合成酵素産生促進剤及び経口用組成物 | |
KR100923539B1 (ko) | 항균활성을 갖는 폴리프로피오네이트 화합물 | |
CN100354292C (zh) | 黄酮类新化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101005 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101007 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4607484 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |